Aurinia Pharma Inc Live Stock Price Today, Share Analysis and Chart

Name: Aurinia Pharmaceuticals Inc: Is Infosys Ltd. worth buying?
Item: Aurinia Pharmaceuticals Inc
Rating: 2.017611125
Author: Trendlyne DVM scores

Risky Value

about

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for ...

15.97 0.03 (0.19%)

86.78% Gain from 52W Low

514.6K

XNAS Volume

XNAS 17 Jul, 2026 3:37 PM (EDT)

Low Financial Strength

27.8 / 100

Affordable Valuation

55.8 / 100

Technically Neutral

50.0 / 100

Risky Value These stocks have weak financials and average momentum. They may be affordable, but investors should exercise caution View Similar Embed DVM

1Yr Price target upside is 6%

7 analysts

Aurinia Pharma Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Aurinia Pharma Inc Live Stock Price Today, Share Analysis and Chart

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for ...

86.78% Gain from 52W Low

SWOT Analysis

Aurinia Pharma Inc Live Price Chart

Aurinia Pharma Inc Live Price Chart